These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 10027508

  • 1. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
    Zhang W, Bymaster FP.
    Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
    [Abstract] [Full Text] [Related]

  • 2. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.
    Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW.
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):87-94. PubMed ID: 8935803
    [Abstract] [Full Text] [Related]

  • 3. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
    Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE.
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):57-73. PubMed ID: 8935801
    [Abstract] [Full Text] [Related]

  • 4. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain.
    Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T.
    J Neural Transm (Vienna); 2000 Mar; 107(3):295-302. PubMed ID: 10821438
    [Abstract] [Full Text] [Related]

  • 5. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS.
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [Abstract] [Full Text] [Related]

  • 6. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
    Campiani G, Nacci V, Bechelli S, Ciani SM, Garofalo A, Fiorini I, Wikström H, de Boer P, Liao Y, Tepper PG, Cagnotto A, Mennini T.
    J Med Chem; 1998 Sep 24; 41(20):3763-72. PubMed ID: 9748351
    [Abstract] [Full Text] [Related]

  • 7. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
    Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO.
    Schizophr Res; 1999 May 04; 37(1):107-22. PubMed ID: 10227113
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB, Nirogi R, Bhyrapuneni G, Ajjala DR, Aleti RR, Palacharla RC.
    J Pharmacol Toxicol Methods; 2017 May 04; 85():22-28. PubMed ID: 28063918
    [Abstract] [Full Text] [Related]

  • 9. Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194a: an analysis of possible mechanisms.
    Goudie AJ, Baker LE, Smith JA, Prus AJ, Svensson KA, Cortes-Burgos LA, Wong EH, Haadsma-Svensson S.
    Behav Pharmacol; 2001 Sep 04; 12(5):303-15. PubMed ID: 11710745
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
    Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA.
    J Clin Psychiatry; 1997 Sep 04; 58 Suppl 10():28-36. PubMed ID: 9265914
    [Abstract] [Full Text] [Related]

  • 11. Differential effects of olanzapine at dopamine D1 and D2 receptors in dopamine depleted animals.
    Ninan I, Kulkarni SK.
    Psychopharmacology (Berl); 1999 Feb 04; 142(2):175-81. PubMed ID: 10102770
    [Abstract] [Full Text] [Related]

  • 12. Olanzapine: a basic science update.
    Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO.
    Br J Psychiatry Suppl; 1999 Feb 04; (37):36-40. PubMed ID: 10211140
    [Abstract] [Full Text] [Related]

  • 13. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.
    Ichikawa J, Kuroki T, Dai J, Meltzer HY.
    Eur J Pharmacol; 1998 Jun 19; 351(2):163-71. PubMed ID: 9686999
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.
    Tarazi FI, Zhang K, Baldessarini RJ.
    J Pharmacol Exp Ther; 2001 May 19; 297(2):711-7. PubMed ID: 11303062
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ, Copinga S, Unelius L, Jackson DM, Wikström HV, Grol CJ.
    Bioorg Med Chem; 1999 Jul 19; 7(7):1263-71. PubMed ID: 10465402
    [Abstract] [Full Text] [Related]

  • 16. Antagonism by pimozide of olanzapine-induced hypothermia.
    Ninan I, Kulkarni SK.
    Fundam Clin Pharmacol; 1999 Jul 19; 13(5):541-6. PubMed ID: 10520726
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.
    Deveney AM, Waddington JL.
    Psychopharmacology (Berl); 1996 Mar 19; 124(1-2):40-9. PubMed ID: 8935799
    [Abstract] [Full Text] [Related]

  • 18. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects.
    Nyberg S, Farde L, Halldin C.
    Neuropsychopharmacology; 1997 Jan 19; 16(1):1-7. PubMed ID: 8981383
    [Abstract] [Full Text] [Related]

  • 19. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 19; 280(1):83-97. PubMed ID: 8996185
    [Abstract] [Full Text] [Related]

  • 20. Examining dopamine D3 receptor occupancy by antipsychotic drugs via [3H]7-OH-DPAT ex vivo autoradiography and its cross-validation via c-fos immunohistochemistry in the rat brain.
    Davoodi N, te Riele P, Langlois X.
    Eur J Pharmacol; 2014 Oct 05; 740():669-75. PubMed ID: 24967534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.